Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type

Journal of Investigative Dermatology

Volumn 134, Issue 1, 2014, Pages 290-292

  Koens, Lianne ^a   Zoutman, Willem H ^a   Ngarmlertsirichai, Passorn ^b   Przybylski, Grzegorz K ^b,c   Grabarczyk, Piotr ^b   Vermeer, Maarten H ^a   Willemze, Rein ^a   Jansen, Patty M ^a   Schmidt, Christian A ^b   Tensen, Cornelis P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD79B ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; RITUXIMAB;

CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; HUMAN; LARGE CELL LYMPHOMA; LETTER; OVERALL SURVIVAL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIMARY CUTANEOUS LARGE B CELL LYMPHOMA LEG TYPE; PRIORITY JOURNAL; SKIN LYMPHOMA; STOP CODON; TUMOR GROWTH;

EID: 84890972820     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.265     Document Type: Letter

References (15)

1. Chu Y, Vahl JC, Kumar D et al. (2011) B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 117: 2227-36
2. Compagno M, Lim WK, Grunn A et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717-21
3. Dal Porto JM, Gauld SB, Merrell KT et al. (2004) B cell antigen receptor signaling 101. MolImmunol 41: 599-613
4. Davis RE, Brown KD, Siebenlist U et al. (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-74
5. Hoefnagel JJ, Dijkman R, Basso K et al. (2005) Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105: 3671-8
6. Honma K, Tsuzuki S, Nakagawa M et al. (2009) TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non- Hodgkin lymphomas. Blood 114: 2467-75
7. Lamason RL, McCully RR, Lew SM et al. (2010) Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. Biochemistry 49: 8240-50
8. Naylor TL, Tang H, Ratsch BA et al. (2011) Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 71: 2643-53
9. Ngo VN, Davis RE, Lamy L et al. (2006) A loss-offunction RNA interference screen for molecular targets in cancer. Nature 441: 106-10
10. Ngo VN, Young RM, Schmitz R et al. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470: 115-9
11. Pham-Ledard A, Cappellen D, Martinez F et al. (2012) MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 132: 2118-20
12. Senff NJ, Noordijk EM, Kim YH et al. (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112: 1600-9
13. Sommer K, Guo B, Pomerantz JL et al. (2005) Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 23: 561-74
14. Wilson WH, Gerecitano JF, Goy A et al. (2012) The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood (ASH Annual Meeting Abstracts) 120: 4039 (abstract)
15. Yang Y, Shaffer AL, Tolga Emre MC et al. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B-cell lymphoma. Cancer Cell 21: 723-37